Berlin - Delayed Quote EUR

Ocugen Inc (2H51.BE)

0.7285

+0.0280

+(4.00%)

As of 8:01:01 AM GMT+1. Market Open.

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clinical trial is anticipated to start in 2Q 2025 MALVERN, Pa., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the U.S. Food and Drug Administra

GlobeNewswire 3 days ago

OCGN
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment

The open-label, dose-escalation trial will explore the effects of different dosage levels of OCU200.

Clinical Trials Arena 13 days ago

OCGN
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related macular degenerati

GlobeNewswire 14 days ago

OCGN
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years100% (9/9) of treated evaluable subjects demonstrated improvement or stabilization in mobility testing, which was only performed up to one yearImprovement in visual function was statistically significant (p=0.01, treated vs untreated eyes), regardless of mutation at two yearsFavorable long-term safety and tolerability profile with no serious adv

GlobeNewswire 17 days ago

OCGN
5 Biotech Breakthrough Stocks to Watch in 2025

It is a good idea to keep an eye on five biotech breakthrough stocks, MDMD, BEAM, ACLX, OCGN and INSM, as they may give great returns in the next 2-3 years

Zacks last month

OCGN

INSM

BEAM
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular Inflammation, anterior ischemic optic neuropathy, or vasculitis MALVERN, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today ann

GlobeNewswire last month

OCGN
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will present at the Oppenheimer Movers in Rare Disease Summit at the Westin Grand Central, New York on Thursday, December 12, 2024. “I have witnessed firsthand the impact that Ocug

GlobeNewswire last month

OCGN
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

MALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL—tak

GlobeNewswire 2 months ago

OCGN
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19 (RP19), and cone-rod dystrophy 3 (CORD3

GlobeNewswire 2 months ago

OCGN
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced positive preliminary efficacy and safety data from the Phase 1 dose-escalation portion of the Phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (dAMD). Key findings include: no dr

GlobeNewswire 2 months ago

OCGN
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of 0% and 5.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

OCGN
Ocugen: Q3 Earnings Snapshot

MALVERN, Pa. AP) — Ocugen, Inc. OCGN) on Thursday reported a loss of $13 million in its third quarter.

Associated Press Finance 2 months ago

OCGN
Q3 2024 Ocugen Inc Earnings Call

Q3 2024 Ocugen Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

OCGN
Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Ocugen Inc (OCGN) secures key regulatory approvals and financing while navigating competitive and financial hurdles in gene therapy development.

GuruFocus.com 2 months ago

OCGN
Ocugen (OCGN) Q3 2024 Earnings Call Transcript

OCGN earnings call for the period ending September 30, 2024.

Motley Fool 2 months ago

OCGN
Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ETSubsequent to quarter-end, closed $30 million in debt financingOCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial approved enrollment for the second phase of the Phase 1/2 clinical trialNew data on Phase 1/2 clinical trials for OCU410, OCU41

GlobeNewswire 2 months ago

OCGN
Ocugen Secures $30 Million in Debt Funding

MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that on November 6, 2024, the Company entered into a new $30 million credit facility with Avenue Venture Opportunities Fund, L.P., a fund of Avenue Capital Group. Proceeds from the facility are intended for general corporate purposes, capital expe

GlobeNewswire 2 months ago

OCGN
Those who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163%

While Ocugen, Inc. ( NASDAQ:OCGN ) shareholders are probably generally happy, the stock hasn't had particularly good...

Simply Wall St. 2 months ago

OCGN
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Progress on OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) and new data from Phase 1/2Preliminary safety and efficacy update on OCU410 Phase 1/2 ArMaDa clinical trial for geographic atrophy (GA)Clinical update on OCU410ST Phase 1/2 GARDian clinical trial for Stargardt diseaseFeaturing patients, investigators and thought leaders MALVERN, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering

GlobeNewswire 3 months ago

OCGN
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Determined the high dose of OCU410ST to be the maximum tolerated doseNo serious adverse events have been reportedApproved proceeding to Phase 2 using high and medium doses of OCU410ST MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410

GlobeNewswire 3 months ago

OCGN

Performance Overview

Return	2H51.BE	S&P 500
YTD	-19.06%	+2.78%
1-Year	+41.62%	+23.27%
3-Year	-73.52%	+36.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ocugen Inc (2H51.BE)

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

5 Biotech Breakthrough Stocks to Watch in 2025

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates

Ocugen: Q3 Earnings Snapshot

Q3 2024 Ocugen Inc Earnings Call

Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Ocugen (OCGN) Q3 2024 Earnings Call Transcript

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Ocugen Secures $30 Million in Debt Funding

Those who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163%

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Performance Overview